South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, ...

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and appetite. GLP-1 is primarily secreted from the intestines, ...

"Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study" was originally created and published by ...

Despite reported slowing of progression, regulators said the evidence on the novel oral agent blarcamesine did not support a ...

A new study published on Thursday, Oct. 24, 2024, showed potentially promising results in Alzheimer's and dementia prevention: It's the third such study that indicates that semaglutides, the active ...

High-sensitivity C-reactive protein (CRP) decreased significantly in the semaglutide group, with estimated treatment ratios ...

A medication designed to slow early Alzheimer’s disease (AD) may soon have a new dosing schedule. The medication, Leqembi, is currently administered via an infusion every two weeks. Once it’s in the ...

Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly volunteers, supporting its advancement into further ...

The first drug found to slow down Alzheimer’s is to be given the green light for use in Britain. Lecanemab, hailed by experts as “the beginning of the end” for the disease, has been found to slow ...

A second drug for the treatment of Alzheimer’s disease was approved Tuesday by the Food and Drug Administration. The drug donanemab, marketed by drugmaker Eli Lilly as Kisunla, was tested in a ...